It is tempting to see abuse-deterrent opioids as a powerful and singular solution that might go a long way toward addressing our nation’s opioid crisis. But, it is not so simple.

A mandate to use abuse-deterrent opioids at an up to twentyfold increase in cost would be staggering to health care systems. For example, the Department of Veterans Affairs spent nearly $100 ...

The U.S. Food and Drug Administration (FDA) last week publicly released a draft guidance on the agency’s outlook on supporting the development of generic versions of approved opioids with abuse ...

Winegarden's study found that an abuse-deterrent formulation can reduce the abuse of opioids by 18% among Medicaid patients and 23% for commercially insured patients.

In fact, the ICER report found that the cost of the current abuse-deterrent opioid prices needed to be cut by 41% to make them cost neutral (i.e., the additional cost of the drugs and the amount ...

Looking Toward Abuse Deterrent Opioids By PRA Health Sciences Nov 7, 2017 11:44am sponsored - PRA Health Sciences Biotech ...

Medscape: Besides supporting the development of abuse-deterrent products, can you briefly describe the other strategies that the FDA is exploring to address the opioid epidemic that may be helpful ...

PALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's estimated that replacing extended-release ...

References: Protega Pharmaceuticals receives FDA approval for RoxyBond™ (oxycodone hydrochloride) immediate-release 10mg tablet with abuse-deterrent technology for management of pain.